The earnings call reflects strong sales performance and successful marketing efforts, indicating significant growth and expansion potential for XDEMVY. While there are challenges in managing expenses and gross-to-net improvements, the positive aspects, including financial stability and strategic pipeline development, outweigh the negatives.

Company Guidance

During Tarsus' Q2 2025 earnings call, the company highlighted several key metrics demonstrating strong performance and growth potential. XDEMVY, the FDA-approved treatment for Demodex blepharitis, achieved over $100 million in net sales with approximately 91,000 bottles dispensed, reflecting significant quarter-over-quarter growth. The direct-to-consumer (DTC) campaign has been a catalyst for growth, evident in the tripling of unaided awareness and a 400% increase in website interactions. Tarsus reported over 20,000 eye care professionals (ECPs) prescribing XDEMVY, with 80% of surveyed ECPs treating across all Demodex blepharitis patient segments. Financially, the gross-to-net discount improved to approximately 45%, with expectations to reach the low 40s by year-end 2025. The company ended the quarter with $381 million in cash and cash equivalents. Looking ahead, Tarsus plans to expand XDEMVY's reach globally and has a promising pipeline, including the TP-04 program for ocular rosacea, set to enter Phase II trials later in the year.

Record-Breaking Sales

In Q2, Tarsus delivered over $100 million in net sales and dispensed approximately 91,000 bottles, marking a 30% sequential quarterly revenue growth.

Successful Direct-to-Consumer Campaign

The DTC campaign significantly increased prescription volumes and awareness, with unaided awareness of XDEMVY tripling and website interactions up nearly 400%.

High Prescriber Engagement

Over 20,000 Eye Care Professionals (ECPs) are now prescribing XDEMVY, with 80% treating across all Demodex blepharitis patient segments.

Strong Financial Position

Gross margins remained flat at 93%, with cash and cash equivalents at approximately $381 million at quarter-end.

Global Expansion Plans

Meetings with regulatory authorities in Japan are on track, and potential European regulatory approval for a preservative-free formulation of XDEMVY is expected in 2027.

Tarsus Pharmaceuticals (TARS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TARS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.36 / -	-0.61	―	―	―
Aug 06, 2025	2025 (Q2)	-0.38 / -0.48	-0.88	45.45% (+0.40)
May 01, 2025	2025 (Q1)	-0.73 / -0.64	-1.01	36.63% (+0.37)
Feb 25, 2025	2024 (Q4)	-0.74 / -0.60	-1.31	54.20% (+0.71)
Nov 13, 2024	2024 (Q3)	-0.94 / -0.61	-1.28	52.34% (+0.67)	―
Aug 08, 2024	2024 (Q2)	-0.92 / -0.88	-1.17	24.79% (+0.29)	―
May 08, 2024	2024 (Q1)	-1.18 / -1.01	-0.88	-14.77% (-0.13)	―
Feb 27, 2024	2023 (Q4)	-1.37 / -1.31	-0.46	-184.78% (-0.85)	―
Nov 09, 2023	2023 (Q3)	-1.35 / -1.28	-0.84	-52.38% (-0.44)	―
Aug 10, 2023	2023 (Q2)	-1.08 / -1.17	-0.24	-387.50% (-0.93)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TARS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$41.64	$47.95	+15.15%
May 01, 2025	$50.30	$47.36	-5.84%
Feb 25, 2025	$45.54	$41.29	-9.33%
Nov 13, 2024	$46.50	$46.65	+0.32%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Tarsus Pharmaceuticals (TARS) report earnings?

Tarsus Pharmaceuticals (TARS) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Tarsus Pharmaceuticals (TARS) earnings time?

Tarsus Pharmaceuticals (TARS) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TARS EPS forecast?

TARS EPS forecast for the fiscal quarter 2025 (Q3) is -0.37.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing